PDP1 and cancer: Nevertheless, after explaining all the pathophysiology, it seems important to shed light on some future possible treatments: on the one hand, medication increasing PDH activity, such as dichloroacetate, seems to halt carcinogenesis by lowering cytosolic lactate production; on the other hand, MCT1 and MCT4 inhibitors seem to have enormous potential in cancer treatment by inhibiting lactate shuttling, even if there is still a lack of specificity (San‐Millán & Brooks, 2017).